Business

Know the Business

Tenet is two very different businesses bolted together: a low-margin chain of 50 acute-care hospitals and a high-margin national platform of 533 ambulatory surgery centers (USPI). The hospital segment is a regulated, labor-heavy utility earning ~10–11% operating margins; USPI is a physician-joint-venture compounder earning ~34–37% margins. Consolidated multiples mask this — about half of recurring operating income comes from the segment that generates one quarter of revenue, and the market is still pricing the company as a single hospital company.

1. How This Business Actually Works

Tenet sells the same thing twice — a surgical procedure — through two very different channels. In the hospital, a knee replacement is reimbursed at inpatient rates (high gross dollars, but heavy fixed cost in nurses, beds, EMTALA obligations and self-pay leakage). In a USPI ambulatory surgery center, the same case is reimbursed at lower gross dollars but with no ER, no overnight stay, no charity-care obligation, and physicians who own equity and bring their book of cases. The dollars per case fall; the margin per case roughly triples.

USPI is 24% of revenue but contributed roughly half of FY2025 segment operating income. Crucially, the next layer down rewrites the picture again. USPI is a portfolio of physician joint ventures: of $1.78B Ambulatory operating income, $805M was distributed to noncontrolling interests (the doctors and health-system partners), so Tenet's economic share is closer to $970M. In the Hospital segment, NCI takes only $155M of $1.73B. After NCI, Tenet keeps roughly 57% from hospitals and 43% from USPI — but USPI's piece grows 6–8% organically while the hospital piece is essentially flat in volume.

The FY2024 spike is not operating: $2.92B of it was a one-time gain on the sale of 14 hospitals to Catholic Health Initiatives, UCI Health and others. Strip it out and FY2024 normalized op margin was ~13.5%. The shape of the business is the steady upward grind from 2020 to 2025 once the divestitures and pandemic noise are removed — that grind is USPI's mix shift, not the hospitals.

2. The Playing Field

Tenet sits in a strange spot in the peer set: smaller and more levered than HCA, more profitable than UHS or CYH, and meaningfully more ambulatory-mix than any of them.

What the comparison reveals: HCA is the structural winner — it operates at twice Tenet's hospital scale, has superior payer leverage, and converts cleanly to cash; the market rewards that with the highest P/E. Pure hospital peers (UHS, CYH) trade at 7x earnings or worse because the market treats acute-care as a regulated commodity with cyclical labor cost risk. Encompass (post-acute rehab) and Surgery Partners (ASC pure-play) trade richer because their economics resemble Tenet's USPI more than its hospitals. Tenet's blended P/E of 12.8x sits between these worlds because the consolidated income statement combines them; the implicit question is whether Tenet should converge upward toward EHC/SGRY or downward toward UHS/CYH.

What "good" looks like in this set is a combination of (a) ambulatory mix above 25% of EBITDA, (b) net leverage below 3x, and (c) commercial managed-care share above 65% of net patient service revenue. Tenet now meets all three (USPI is ~50% of EBITDA, leverage 2.83x ex-NCI, managed care 70% of hospital revenue). Two years ago it met none.

3. Is This Business Cyclical?

Hospital operators are not cyclical in the GDP sense — Americans get sick on a schedule that ignores the business cycle — but they are intensely policy-cyclical and labor-cyclical, and those cycles dominate everything else.

Three cycle vectors actually move the needle:

Reimbursement / policy cycle. This is the dominant one. The Affordable Care Act expanded Medicaid in 2014 and lifted hospital admissions; the COVID emergency funding lifted 2020–2021; the One Big Beautiful Bill Act (OBBBA, July 2025) and the late-2025 expiration of enhanced premium tax credits are now running the other way. Management already flags that exchange revenues — about 6% of consolidated revenue — fell ~10% in Q1 FY2026, with most of the headwind expected through 2027. The OBBBA's Medicaid work requirements, supplemental-payment caps and tighter eligibility checks take effect in 2027 and Tenet has flagged it cannot yet quantify the impact.

Labor cycle. 2022 was the recent textbook: contract nurse rates spiked, salaries-wages-benefits absorbed 200+ basis points of margin, and Tenet's operating margin compressed from 13.5% to 10.9% in a year despite revenue holding flat. By 2025 SWB had fallen back to 40.8% of revenue. California's new healthcare-worker minimum wage (October 2024 onward) and the 20% unionization rate in hospital ops are the standing risks.

Volume / acuity cycle. Smaller and more nuanced. Q1 FY2026 saw a 41% drop in respiratory admissions (a mild flu season) trim hospital admissions growth by 90bps. Outpatient migration is a structural multi-decade trend, not a cycle — and it favors Tenet because USPI captures it.

USPI itself is far less cyclical: ASC volumes are tied to elective procedures (orthopedics, ophthalmology, GI), commercial pricing rises annually, and ASCs do not carry charity-care or ER obligations. The 2022 labor shock barely touched USPI margins. The right framing is that hospitals carry the cycle exposure; USPI doesn't.

4. The Metrics That Actually Matter

Forget gross margin and revenue growth — they conflate the segments. The five metrics below are what determine whether Tenet creates or destroys value in any given year.

The metric most analysts get wrong is the last one. Headline EBITDA looks healthy, but ~$960M flowed to USPI's physician partners in 2025 before Tenet ever saw it — about 24% of consolidated EBITDA. Free cash flow after NCI is the true cash flow to Tenet shareholders, and management's 2026 guide of $1.6–$1.83B (after a $150M one-off Conifer tax payment) implies a ~$1.87B run-rate. That is the number that funds buybacks and debt paydown, not the consolidated $4B EBITDA figure.

The metric most management teams over-emphasize is utilization of licensed beds (49.8% in Q4 FY2025). It barely moves and barely matters at this level — what matters is mix within those beds (commercial vs. Medicaid vs. uninsured) and acuity per case.

5. What Is This Business Worth?

Value here is determined by two separable engines, not one. Treating Tenet as a single hospital operator at a blended P/E ignores that USPI deserves an ASC-platform multiple while the hospitals deserve a commodity-acute-care multiple. Sum-of-the-parts is the right lens.

Binder Error: Set operations can only apply to expressions with the same number of result columns

What the SOTP teaches: at the low end the market is roughly fair on Tenet — you are paying for a struggling acute-care utility plus a USPI stake at trough multiples. At the high end there is meaningful upside because USPI alone, valued like the only listed pure-play (Surgery Partners, which Bain offered to take private at ~12x EBITDA in 2024), accounts for the majority of the market cap before you assign anything to the hospitals. The decisive question is not the precise multiple — it is whether you believe USPI's economics deserve to be looked at separately at all.

The wrong way to value this is a single P/E or EV/EBITDA. The blended 7.85x EV/EBITDA looks cheap until you remember (a) ~24% of EBITDA leaves the door as NCI distributions; (b) the hospital half deserves something closer to 5–6x; and (c) leverage of $10B net debt amplifies any error in either direction. The right way is two engines, two multiples, one debt stack, one cash pile.

6. What I'd Tell a Young Analyst

Stop treating Tenet as a hospital company. It is now an ASC platform with a hospital ballast. Build USPI on its own line — same-facility revenue growth, net revenue per case, EBITDA, NCI distributions, M&A spend — and judge it against Surgery Partners and Optum's SCA Health, not against HCA.

The single most important number is free cash flow after NCI, not EBITDA. A 24% leakage to USPI's physician partners is structural and growing — every USPI acquisition adds revenue on Tenet's income statement and a partner check below it. Anyone modeling consolidated EBITDA without subtracting NCI is double-counting.

Underwrite three risks honestly and stop arguing about the rest. (1) The OBBBA hits in 2027 and Tenet has not quantified it; states will implement work requirements and provider-tax caps differently and four of Tenet's eight hospital states have not expanded Medicaid. (2) Premium tax credits expired end of 2025 — about half the headwind is in Q1 numbers, and the second half is coming. (3) California seismic compliance for hospitals by 2030 is an unquantified capex liability that management has refused to size. Everything else (denials, nurse wages, cyber) is noise around these.

What the market may be underestimating: the Conifer ownership consolidation (Tenet returns to 100% from 76.2% effective January 2026, with $1.9B of payments from CommonSpirit over three years) is a clean cash-flow positive event that has been buried under the OBBBA narrative. The buyback ($1.39B in 2025, another $318M in Q1 2026, $1.49B remaining authorization) compounds the ownership story for patient holders — share count is down 15% in four years.

What would change the thesis: a USPI acquisition of size from a strategic, a Tenet decision to spin USPI public, or — bearishly — a single state (Texas or Florida) implementing OBBBA Medicaid changes more aggressively than peers. Watch state-level supplemental-payment program approvals quarterly; that is the leading indicator.